Hi Friends, Im Glad to have you at my site.
This site is an interesting collection of
news, articles, snippets etc. on various topics that I like !!
Recent Developments, Views & Opinions in Pharma:
Most deals in 2015 are with companies focussing on a specialised portfolio. Cipla-Serum; Famycare-Mylan & Valeant-Salix...Read on...2015 - Deals in Nice Areas
A quick recap of the key events that shaped 2013: GDUFA fees, Obamacare, Pay-for-delay and the key M&As that were closed.
Hanmi's version is non "AB" and not directly equivalent to the original innovator drug. The approval of esompeprazole strontium as an NDA product which differs only in the "salt" is quite a significant & a noteworthy development.
The below article provides clarifications & insights on approvals via the 505(b)(2) pathways and its advantages.
Read More: http://www.fiercepharma.com/story/appeals-court-frees-hanmi-double-damage-risk-its-nexium-copy/2013-12-19
companies fully focussed on this space like Virbac. As per the article (link to the source article given), the burgeoning companion animal business (pets 'health) that generated about $8 billion in global sales last year. Another $14 billion in revenue came from medicines and vaccines for the global food animal market. The research firm Global Industry Analysts predicted the world animal medication market will top $43 billion by 2018.
No wonder we see activities back home in India, where Shasun is forming a JV with Sequent to develop Vet API & Formulations.
See Related Articles:
The Emergence of the Era of Biosimilars: The current Generics boom is expected to last uptil 2015 and one could question the growth opportunities for pharma companies beyond 2015. The next big opportunity for pharma, post the generics era seems to be with biosimilars. We may be nearing the end of the big blockbuster molecules from chemical synthesis and moving more & more towards biologics.
In fact, Hyderabad as a pharma-hub developed only because of Dr. Anji Reddy's initial work with IDPL & SOL and his entrepreneurial capabilities. And also most pharma companies today in Hyderabad & the South India, would most-likely have some common origins or links to the erstwhile SOL or IDPL. In many ways therefore, I believe, the Indian pharma industry owes a lot to Dr. Anji Reddy, a pioneering entrepreneur, who has not only built a global company, but has developed an entire industry in India that is now globally recognised to be the third largest supplier of pharmaceuticals by volume in the world today.We salute Dr. Reddy and will certainly miss him.
The Agila valuations have only opened our eyes, but we have already seen a number of deals of-late in this space - Hospira/Orchid; Claris/Otsuka and now Agila. Point to note is even in India there are very limited players in injectables with regulatory approvals & ready dossiers, which explains the valuations that Agila seems to get.
Contract Manufacturing Magazine, pegs the injectables market to grow at a whopping 42% and to $17 Billion by 2020.
Interesting Articles & Reports on the Pharma Industry:
A Compilation of "The Sacred Space" from various issues of The Times of India